41270-66-0

Basic information

• Product Name: 5-chloro-2,3-diphenylpyrazine
• Synonyms: 2-Chloro-5,6-diphenylpyrazine;Pyrazine, 5-chloro-2,3-diphenyl-
• CAS NO: 41270-66-0
• Molecular Formula: C₁₆H₁₁ClN₂
• Molecular Weight: 266.72494
• EINECS: 1592732-453-0
• Product Categories: Selexipag intermediate
• Mol File: 41270-66-0.mol

Chemical Properties

• Melting Point: 126-128℃ (methanol )
• Boiling Point: 145°C/0.001mmHg(lit.)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: -2.16±0.10(Predicted)
• CAS DataBase Reference: 5-chloro-2,3-diphenylpyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-2,3-diphenylpyrazine(41270-66-0)
• EPA Substance Registry System: 5-chloro-2,3-diphenylpyrazine(41270-66-0)

Safety Data

• Hazardous Substances Data: 41270-66-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-chloro-2,3-diphenylpyrazine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, 5-chloro-2,3-diphenylpyrazine serves as a starting material for the development of novel chemical entities. Its reactivity and structural features make it an attractive candidate for further modification and exploration of its potential applications.
Used in Prostacyclin Receptor Agonists:
5-chloro-2,3-diphenylpyrazine has been identified as a potential component in the development of a novel class of prostacyclin receptor agonists. These agonists have significant implications in the treatment of various medical conditions, such as cardiovascular diseases and pulmonary hypertension, due to their ability to mimic the effects of prostacyclin, a potent vasodilator and inhibitor of platelet aggregation.

Upstream product

• 18591-57-6 2,3-Diphenyl-6-hydroxypyrazine 
• 61578-13-0 2,6-diphenylpyrazine 1-oxide 
• 243472-82-4 2,3-diphenyl-5-trimethylsilanyloxy-pyrazine 
• 18591-57-6 5,6-diphenyl-2-hydroxypyrazine 
• 1588-89-2 2,3-diphenylpyrazine 
• 1489-06-1 2,3-diphenyl-5,6-dihydropyrazine 
• 134-81-6 benzil 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 

Downstream Products

• 110249-96-2 2-(5,6-diphenyl-pyrazin-2-ylamino)-ethanol 
• 475086-75-0 4-[N-(5,6-diphenylpyrazine-2-yl)-N-isopropylamino]-1-butanol 
• 73444-24-3 N-(5,6-diphenylpyrazin-2-yl)(methyl)amine 
• 475086-91-0 5,6-diphenyl-2-[5-(2-tetrahydropyranyloxy)-1-pentyn-1-yl]pyrazine 
• 475086-94-3 1-(5,6-diphenylpyrazin-2-yloxy)-4-(2-tetrahydropyranyloxy)butane 
• 1265295-08-6 1,1,2,2,3,3,4,4-d8-4-((5,6-diphenylpyrazin-2-yl)(perdeutero-propan-2-yl)amino)butan-1-ol 
• 1265295-18-8 4-((5,6-diphenylpyrazin-2-yl)(perdeutero-propan-2-yl)amino)butan-1-ol 
• 1265295-13-3 1,1,2,2,3,3,4,4-d8-4-((5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino)butan-1-ol 
• 1265295-09-7 tert-butyl 2-(1,1,2,2,3,3,4,4-d8-4-((5,6-diphenylpyrazin-2-yl)(perdeutero-propan-2-yl)amino)butoxy)acetate 
• 1265295-21-3 2-(4-((5,6-diphenylpyrazin-2-yl)(perdeutero-propan-2-yl)amino)butoxy)-N-(methylsulfonyl)acetamide 
• 1265295-20-2 2-(4-((5,6-diphenylpyrazin-2-yl)(perdeuteropropan-2-yl)amino)butoxy)acetic acid 
• 1265295-19-9 tert-butyl 2-(4-((5,6-diphenylpyrazin-2-yl)(perdeutero-propan-2-yl)amino)butoxy)acetate 
• 1265295-16-6 N-(methylsulfonyl)-2-(1,1,2,2,3,3,4,4-d8-4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetamide 
• 1265295-15-5 2-(1,1,2,2,3,3,4,4-d8-4-((5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy)acetic acid 

Relevant articles and documents

Method for preparing selexipag intermediate

The invention discloses a preparation method of a selexipag intermediate 5-chloro-2,3-diphenyl piperazine. The preparation method comprises the following steps: carrying out a reaction on 5,6-diphenyl-2-hydroxypyrazine with phosphorus oxychloride for 10-12 hours under heating, wherein an acid-binding agent is added into an organic solvent environment; adding the reaction product into ice water forcrystallization, and performing filtration and washing to obtain the 5-chloro-2,3-diphenyl piperazine. By means of the method, the defects of an existing method are overcome, wherein the use amount of phosphorus oxychloride is reduced, phosphorus-containing sewage discharge is reduced, and the obtained intermediate is high in purity, good in yield, simple to operate and suitable for industrial production.

A preparation method of a diphenyl pyrazine compound

A diphenyl pyrazine compound I having a novel structure is developed according to structures of existing IP receptor agonists and a preparation method of the compound I is provided. The method is simple to operate and high in yield, and the yield of each step is higher than 70% preferably. The compound I can be efficiently prepared by the method. The invention also provides a preparation method ofan intermediate compound X for preparing the compound I, and the method has high yield and high product purity.

PROCESS FOR THE PREPARATION OF DIPHENYLPYRAZINE DERIVATIVES

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

AN IMRPOVED PROCESS FOR THE PREPARATION OF SELEXIPAG OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention provides an improved process for Selexipag of formula (I) or its pharmaceutically acceptable salts.

3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1

Methylation of histone lysine residues plays important roles in gene expression regulation as well as cancer initiation. Lysine specific demethylase 1 (LSD1) is responsible for maintaining balanced methylation levels at histone H3 lysine 4 (H3K4). LSD1 is a drug target for certain cancers, due to important functions of methylated H3K4 or LSD1 overexpression. We report the design, synthesis, and structure-activity relationships of 3-(piperidin-4-ylmethoxy)pyridine containing compounds as potent LSD1 inhibitors with Ki values as low as 29 nM. These compounds exhibited high selectivity (>160×) against related monoamine oxidase A and B. Enzyme kinetics and docking studies suggested they are competitive inhibitors against a dimethylated H3K4 substrate and provided a possible binding mode. The potent LSD1 inhibitors can increase cellular H3K4 methylation and strongly inhibit proliferation of several leukemia and solid tumor cells with EC50 values as low as 280 nM, while they had negligible effects on normal cells.

Studies on pyrazines. 35 [1]. An improved synthesis of bromopyrazines from hydroxypyrazines

The synthesis of bromopyrazines from hydroxypyrazines was successfully effected by the procedure via trimethylsilyloxypyrazines, the sequence of which proceeds under mild conditions and does not require the isolation of intermediate.

Syntheses and Reactions of Some 2,3-Disubstituted Pyrazine Monoxides

The reactions of 2,3-dimethyl- (4), 2,3-diphenyl- (6), and 2-methyl-3-phenyl-pyrazine monoxides (8 and 9) with phosphoryl chloride and acetic anhydride resulted in giving monochloro- and monoacetoxy-pyrazines in almost all cases.However, the reaction of 6 with acetic anhydride afforded exceptionally a diacetoxydihydropyrazine.These products were converted further to hydroxy or dichloro derivatives.